entertainment -WSS

entertainment

author：explore 2025-10-02 11:10:40 - browse：393

An Ozempic pen connects dots that make up the shape o a brain — coverage from STAT — ILLUSTRATION: CHRISTINE KAO/STAT; PHOTOS: ADOBE

Drugs like Ozempic and Wegovy — already game changers for diabetes and obesity — are being studied to treat an entirely different growing health problem: mental health illnesses, including depression and bipolar disorder.

Early data and anecdotes suggest that this class of GLP-1 drugs could help patients feel less depressed and anxious. The treatment may also fight the decline in cognitive and executive function that many people with mental health disorders experience, like worsening memory and losing the ability to focus and plan.

If further research yields positive results, it could drive even more demand for the highly popular GLP-1 treatments, which have increasingly been shown to help with problems across the body, such as heart and kidney complications. And especially if the cognitive benefits are proven out, the GLP-1 drugs would plug a critical gap in current treatments for depression, since most depression drugs help with mood, but close to none address cognitive symptoms that affect memory and attention.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

explore

WSS

The most pressing bird flu mysteries scientists want answered

How CO2 helps viruses stay alive longer in the air

BD to buy Edwards patient monitoring unit for $4.2 billion

Data don't support strong claims for Covid

For pregnant people, addiction treatment shouldn't mean a call to child protective services

ASCO: Palliative care found as helpful given virtually as in person

focus

entertainment

focus

Anesthesiologist group: stop taking Ozempic before surgery

STAT wants to know your pick for a great summer read or listen

Bright Health sells Medicare Advantage business to Molina

'Little Tech' descents on D.C., wanting a say in how AI is regulated

The high cost of giving birth even with insurance

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Jerome Adams on the need for new antivirals for Covid

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Peter Hotez and the public health issue of online harassment

Intellia reports positive results for its CRISPR

explore

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Change Healthcare can notify patients about the breach, HHS says

Medicare Advantage's lean provider networks lead CMS complaints

FTC loses bid to block Novant's North Carolina hospital merger

ASCO Daily Recap: CAR

Medicare Advantage's lean provider networks lead CMS complaints

knowledge

explore

leisure time

focus